With members from around the world focused on learning about Generic Drugs and Quality Control; this is your best opportunity to reach the largest assemblage of participants from the Generic Drugs Community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new Techniques in Generic Drugs and Quality Control, and receive name recognition at this 2-day online event.

Track 1: Best Practices & Strategies for Generic Drug Development

Spurring innovation is required for development in generics field, advanced scientific methods, quality data and the use of sophisticated quantitative methods and computational methods are to be implemented, A specific category of drugs that are at times been difficult to make equivalent generics(complex generics) represent some very expensive drugs and are widely used generics, the products with complex active ingredients such as peptides, polymeric compounds, complex mixtures of Active pharmaceutical ingredients(API) Complex formulations such as liposomes, colloids etc. Drugs with complex route of delivery such as topical drugs and ophthalmological products that are often formulated as suspensions.

Track 2:Modernization of Bioequivalence Standards for Generic Products

Bioequivalence (BE)/bioavailability(BA) contemplates assume a significant part in drug improvement both for new medication and their conventional reciprocals, these investigations are additionally done before the endorsement of medication (post endorsement period) and are communicated in fundamental openness measures, like Area under plasma Concentration-Time curve(AUC) and greatest focus C-max these actions are accepted to relate with security and viability out comes that may communicated by biomarkers. This (BA), (BE) contemplates give significant data in generally set of information that guarantees the security and adequacy to the experts and patients.

Track 3: Application of Quantitative systems pharmacology (QSP)

QSP is a quantitative stage that covers a wide range of devices, of which physiologically based models and quantitative clinical pharmacology (QCP) depicts drug testimony and related changeability in individuals. In nonexclusive medications, QP approaches coordinate natural, physiological and drug properties to set up clinically pertinent bioequivalence (BE). QCP approaches are fundamental to assess plan and affectability to lessen cost and season of complex medication improvement.

Track 4: Bioequivalence approaches for complex injectable API and formulations

Track 6: Pharmaceutical Quality Assurance

The motivation behind Quality Assurance is to guarantee that medication arriving at each customer or patient is protected, viable, and fulfills quality guidelines. A far reaching quality confirmation program incorporates both specialized and administrative exercises, numerous zones inside a medical care framework are associated with quality affirmation, including acquisition, drug store, clinical, nursing divisions, just as medication therapeutics board by acquiring quality items which are protected and successful through organized choice and obtainment techniques, keeping up nature of items through the proper stockpiling, checking and conveyance and recommending strategies.

Track 7: Challenges of Manufacturing Generic Drugs

Track 9: Challenges of Marketing Generic Drugs

Albeit the quicker endorsements of nonexclusive item incouraging, there are as yet numerous difficulties to bring new monetary and reasonable item into the market that empowers makes to make a few benefits and stay above water as the expense of making conventional medications is same as marked medications, yet marked medications appreciate the more noteworthy benefits on account of patent insurance. 

Generic Drug Market by Brand (Branded Generic and Pure Generic) for Central Nervous System (CNS), Dermatology, Respiratory, Cardiovascular, Oncology, and Other Therapeutic Applications - Global Industry Perspective, According to the market analysis report, the International Generic Drug market estimated to be across 200.20 Billion USD in 2015 and is expected to reach approximately USD 380.60 billion by 2021, growing at a CAGR of about 10.8 % from 2016 and 2021.

It is driven by the factors such as cost-effectiveness and135 billion worth patented drugs expiry and Government initiatives has given it a competitive lead over the branded drugs in the market, Nearly $150 Billion USD worth drug patents are about to expire in 2020 which can drive Generic drug market into profits.

North America is beholder of the largest share in the generic drug market, In US 89% of the prescribed drugs are Generic and the demand is high for generic drugs, In the Asia pacific region India and China dominated the Generic drug market in volume, total Indian generic drugs market was around 21billion USD in the year 2015 mainly due the Indian companies getting international regulatory approvals like U.S FDA, MHRA.UK, TGA Australia and MCC South Africa. Brazil was the largest Generic market in Latin America it is due to the sale of Generic medicine was accounted for 23% and will remain to be dominant in forecast period due to high demand and increasing development in the pharma sector. Europe is observed to show significant growth in Generic drug market as result of prevalence of chronic diseases and government support.